熱門資訊> 正文
Clearside Biomedical自愿申请破产
2025-11-24 20:15
- Intended to Maximize Stakeholder Value Through a Structured Process.
- Validated SCS Microinjector Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential.
- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy.
- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。